Tag: GLP-1 agonists

Malik and Petersen publish study on new obesity pharmacotherapies 

On July 24, Is-haq Malik, MD and Max Petersen, MD, PhD had their research titled “Glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, and glucagon receptor poly-agonists: a new era in obesity pharmacotherapy,” published in “Obesity Society.”  The purpose of the study was to assess newly approved medications for treating obesity. “Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, […]

Carmichael publishes article on GLP-1 Receptor Agonists

Kim A. Carmichael, MD published a recent article in the February 2022 issue of Consultant 360 titled, “What Do You Need to Know About GLP-1 Receptors Agonists?”  GLP-1 agonists, otherwise known as glucagon-like peptide 1 agonists, are an important class of medications for patients diagnosed with type 2 diabetes.  As the author and series editor, […]